H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Homology Medicines (FIXX – Research Report) today and set a price target of $20.00. The company's shares closed last Friday at $1.55, close to its 52-week low of $1.33. According to TipRanks.com, Trucchio is ranked 0 out of 5 stars with an average return of -25.9% and a 24.3% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as Freeline Therapeutics Holdings, Arrowhead Pharmaceuticals, and Milestone Pharmaceuticals. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Homology Medicines with a $7.85 average price target, implying a 370.1% upside from current levels.
https://www.tipranks.com/news/blurbs/h-c-wainwright-thinks-homology-medicines-stock-is-going-to-recover-2?utm_source=advfn.com&utm_medium=referral
Homology Medicines (NASDAQ:FIXX)
Historical Stock Chart
From Jul 2022 to Aug 2022 Click Here for more Homology Medicines Charts.
Homology Medicines (NASDAQ:FIXX)
Historical Stock Chart
From Aug 2021 to Aug 2022 Click Here for more Homology Medicines Charts.